Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
ARQT moved a median of -0.04% 30 minutes after news, and +0.38% by the close. How ARQT actually reacts to news — the realized, point-in-time move the market made, measured across 599 labeled events over the last three years with zero look-ahead.
ARQT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 48% | 598 |
| 30-min | -0.04% | 50% | 598 |
| 60-min | -0.09% | 49% | 598 |
| to close | +0.38% | 54% | 594 |
| Middle 50% of ARQT reactions | -1.19% to +1.57% |
|---|---|
| Median reaction (30-min) | -0.04% |
| Measured reactions | 599 |
Half of all Arcutis Biotherapeutics, Inc. - Common stock news events land between -1.19% and +1.57% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ARQT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 71 | -0.55% | 37% | -1.60% |
| Price-target raises | 14 | +0.40% | 64% | -0.54% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ARQT ranks against every other measured name →
That’s how ARQT usually reacts — get an email when it moves on news →Email me when ARQT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARQT's baseline. Nothing else.
Recent ARQT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical | Press release | GlobeNewswire | -0.08% | +8.49% | |
| Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award | Press release | GlobeNewswire | -1.46% | -5.71% | |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.34% | +0.24% | |
| Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options | Press release | GlobeNewswire | +1.40% | -1.69% | |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.56% | -1.81% | |
| Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | GlobeNewswire | -1.31% | -1.62% | |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.89% | — | |
| Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.44% | -8.77% | |
| Form 10-Q Arcutis Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.44% | -8.77% | |
| Form 8-K Arcutis Biotherapeutics, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -6.44% | -8.77% | |
| Arcutis Expands Board of Directors with Appointment of Chris Peetz | Press release | GlobeNewswire | -1.24% | -0.18% | |
| Form 8-K Arcutis Biotherapeutics, For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | +3.64% | |
| Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 | Press release | GlobeNewswire | -1.24% | -0.18% | |
| FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | Press release | GlobeNewswire | -0.14% | +4.13% | |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.54% | +0.89% | |
| Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications | Press release | GlobeNewswire | -0.37% | -3.42% | |
| FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 | Press release | GlobeNewswire | -0.37% | -3.42% | |
| Form 8-K Arcutis Biotherapeutics, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | +2.56% | |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.12% | +0.42% | |
| New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology | Press release | GlobeNewswire | -0.63% | +2.69% | |
| Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | -0.28% | -1.12% | |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.30% | -0.38% | |
| Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.72% | -9.46% | |
| Form 10-Q Arcutis Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.72% | -9.46% | |
| Form 8-K Arcutis Biotherapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | -9.46% | |
| Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months | Press release | GlobeNewswire | +1.59% | +0.43% | |
| Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Press release | GlobeNewswire | -0.21% | +0.64% | |
| Form ARS Arcutis Biotherapeutics, For: Apr 21 | SEC filing · Form ARS | SEC EDGAR | -0.21% | +0.64% | |
| Form DEF 14A Arcutis Biotherapeutics, For: Apr 21 | SEC filing · Form DEF | SEC EDGAR | -0.21% | +0.64% | |
| Form DEFA14A Arcutis Biotherapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.21% | +0.64% | |
| Form S-8 Arcutis Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.21% | +0.64% | |
| Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 | Press release | GlobeNewswire | -0.37% | -1.51% | |
| Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.57% | +1.05% | |
| Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting | Press release | GlobeNewswire | -0.56% | -0.14% | |
| Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting | Press release | GlobeNewswire | +0.85% | -0.94% | |
| Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology | Press release | GlobeNewswire | +2.01% | -0.97% | |
| Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth | Press release | GlobeNewswire | +1.60% | +1.14% | |
| Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis | Press release | GlobeNewswire | -0.79% | -1.83% | |
| Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference | Press release | GlobeNewswire | -0.86% | -3.66% | |
| Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.97% | +3.18% | |
| Form 10-K Arcutis Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.97% | +3.18% | |
| Form 8-K Arcutis Biotherapeutics, For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -6.97% | +3.18% | |
| Form S-3ASR Arcutis Biotherapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | -6.97% | +3.18% | |
| Form S-8 Arcutis Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | -6.97% | +3.18% | |
| Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments | Press release | GlobeNewswire | +0.96% | +3.45% | |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.02% | +3.09% | |
| Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis | Press release | GlobeNewswire | -1.00% | +2.16% | |
| Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa | Press release | GlobeNewswire | -0.19% | +2.02% | |
| Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference | Press release | GlobeNewswire | +0.30% | -0.80% | |
| Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions | Press release | GlobeNewswire | -0.54% | +3.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARQT section they belong to.
Where else ARQT is measured.
ARQT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Arcutis Biotherapeutics, Inc. - Common stock's median reaction calculated?
Every labeled ARQT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 599 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of ARQT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARQT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.